A new challenge for precision medicine: selecting major contributing risk factors
Inflammation expert opinionsAug. 27, 2017 - ESC 2017, Barcelona, Spain
Video navigation menu
- Despite lipid lowering, a residual risk remains in atherosclerosis 00:15
- Can CV outcomes be improved by inhibiting inflammation, without inducing immune suppression? 00:39
- Can IL-1β antibody further reduce residual risk? 01:12
- IL-1β inhibition results in reduction of CV risk 01:38
- Implications for today’s clinical practice 02:27
- The challenge for precision medicine: selecting major contributing risk factors 03:20
The CANTOS trial is the first in a series of trials that test the hypothesis that inhibiting inflammation can lower residual CV risk. The results of this trial indeed confirm this hypothesis, suggesting that from now on, targeting inflammation may need to be considered in patients on lipid-lowering therapy with residual inflammatory CV risk.
These inflammation expert opinion videos are aimed to provide guidance and perspectives on the implications of the CANTOS trial and other trials addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.
Prof. Erik Stroes is Internist Vascular Medicine at the Dept. of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
Funding to produce this video was provided by an unrestricted educational grant from Novartis.